ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions

This study has been completed.

Sponsored by: Roxane Laboratories
Information provided by: Roxane Laboratories
ClinicalTrials.gov Identifier: NCT00618059
  Purpose

The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine tablets, 7.5 mg, to SALAGEN® Tablets, 7.5 mg (MGI) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.


Condition Intervention
Dry Mouth
Drug: Pilocarpine

ChemIDplus related topics:   Pilocarpine    Pilocarpine hydrochloride    Pilocarpine nitrate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study
Official Title:   A Single Dose, Two-Period, Two-Treatment, 2-Sequence Crossover Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fed Conditions

Further study details as provided by Roxane Laboratories:

Primary Outcome Measures:
  • Bioequivalence [ Time Frame: Baseline, Two period, Seven day washout ] [ Designated as safety issue: No ]

Enrollment:   28
Study Start Date:   August 2004
Study Completion Date:   August 2004
Primary Completion Date:   August 2004 (Final data collection date for primary outcome measure)

  Eligibility
Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

  • Positive test for HIV, Hepatitis B, or Hepatitis C.
  • Treatment with known enzyme altering drugs.
  • History of allergic or adverse response to Pilocarpine or any comparable or similar product.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00618059

Locations
United States, Texas
CEDRA Clinical Research, LLC    
      Austin, Texas, United States, 78759

Sponsors and Collaborators
Roxane Laboratories

Investigators
Principal Investigator:     Daniel V Freeland, DO     CEDRA Clinical Research, LLC    
  More Information


Responsible Party:   Roxane Laboratories, Inc. ( Elizabeth Ernst, Director, Drug Regulatory Affairs and Medical Affairs )
Study ID Numbers:   PILO-04
First Received:   January 15, 2008
Last Updated:   February 15, 2008
ClinicalTrials.gov Identifier:   NCT00618059
Health Authority:   United States: Institutional Review Board

Study placed in the following topic categories:
Malnutrition
Pilocarpine
Xerostomia

Additional relevant MeSH terms:
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Agonists
Autonomic Agents
Miotics
Physiological Effects of Drugs
Muscarinic Agonists
Peripheral Nervous System Agents
Cholinergic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers